Pharmaceutical

Self-amplifying RNA and vaccine innovation: getting from concept to clinic

Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant advantages

May 29, 2024 - 04:00
Self-amplifying RNA and vaccine innovation: getting from concept to clinic
Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant advantages
Read the original article

Tags:

Previous Article

Vasomune wins FDA fast track designation for lung condition treatment

Next Article

Biotech’s road to recovery with 46% increase in Q1 venture funding

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Magazine: Enhancing therapy adherence with prodrugs

Magazine: Enhancing therapy adherence with prodrugs

Sep 22, 2024

STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer

STAT+: Pharmalittle: FDA rejects Merck cough medicine; ...

Dec 21, 2023

STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data

STAT+: Pharmalittle: U.K. approves world’s first CRISPR...

Nov 17, 2023